Lubna Al-Asoom

Dr. Lubna Al-Asoom

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JKJOHRA KHAN
JOHRA KHAN
LALubna Al-Asoom
Lubna Al-Asoom
AAAhmed Alsunni
Ahmed Alsunni
NRNazish Rafique
Nazish Rafique
RLRabia Latif
Rabia Latif
J Francis BorgioJ Francis Borgio
J Francis Borgio
Migraine is a neurological ailment that is characterized by severe throbbing unilateral headache and associated with nausea, photophobia, phonophobia and vomiting. A full and clear mechanism of the pathogenesis of migraine, though studied extensively, has not been established yet. The current available information indicates an intracranial network activation that culminates in the sensitization of the trigemino-vascular system, release of inflammatory markers, and initiation of meningeal-like inflammatory reaction that is sensed as headache. Genetic factors might play a significant role in deciding an individual's susceptibility to migraine. Twin studies have revealed that a single gene polymorphism can lead to migraine in individuals with a monogenic migraine disorder. In this review, we describe recent advancements in the genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. We also discuss the potential roles of genetic and abnormal factors, including some of the metabolic triggering factors that result in migraine attacks. This review will help to accumulate current knowledge about migraine and understanding of its pathophysiology, and provides up-to-date prevention strategies.

1 June 2020 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
NRNazish Rafique
Nazish Rafique
LALubna Al-Asoom
Lubna Al-Asoom
AAAhmed Alsunni
Ahmed Alsunni
FSFarhat Nadeem Saudagar
Farhat Nadeem Saudagar
LALatifah Abdullah Almulhim
Latifah Abdullah Almulhim
GAGaeda Khaled Alkaltham
Gaeda Khaled Alkaltham
Purpose: The objective of this study was to find out the association between mobile use and physiological parameters of poor sleep quality. It also aimed to find out the prevalence of mobile-related sleep risk factors (MRSRF) and their effects on sleep in mobile users. Materials and Methods: This cross-sectional study was conducted on 1925 students (aged 17– 23yrs) from multiple Colleges of Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. The study tools used were Pittsburgh sleep quality index (PSQI) and MRSRF online questionnaires. Results: The mean age (±SD) of participants was 19.91 ± 2.55 years. Average mobile screen usage time was 8.57± 4.59/24 hours, whereas average mobile screen usage time in the bed after the lights have been turned off was 38.17± 11.7 minutes. Only 19.7% of subjects used airplane mode, while 70% kept the mobile near the pillow while sleeping. The blue light filter feature was used by only 4.2% of the participants. “Screen usage time of ≥ 8 hours” was positively correlated with sleep disturbances and decrease in the length of actual sleeping time (p =0.023 and 0.022). “Using the mobile for at least 30 minutes (without blue light filter) after the lights have been turned off” showed positive correlation with poor sleep quality, daytime sleepiness, sleep disturbances and increased sleep latency (p= 0.003, 0.004 and 0.001). “Keeping the mobile near the pillow while sleeping” was also positively correlated with daytime sleepiness, sleep disturbances and increased sleep latency (p =0.003, 0.004 and 0.001). Conclusion: This study concludes that using mobile screen ≥ 8 hours/24 hours, using the mobile for at least 30 minutes before sleeping after the lights have been turned off and keeping the mobile near the pillow are positively associated with poor sleep quality. Moreover, we observed that MRSRF were highly prevalent amongst the mobile users.

1 July 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
ASAyad Salem
Ayad Salem
Noor Al-KhathlanNoor Al-Khathlan
Noor Al-Khathlan
AAAbdulelah Fawzi Alharbi
Abdulelah Fawzi Alharbi
TATurki Alghamdi
Turki Alghamdi
SASaleh AlDuilej
Saleh AlDuilej
Hussein SabitHussein Sabit
Hussein Sabit
Background: The sequelae of COVID-19 pneumonia on pulmonary function and airways inflammation are still an area of active research. Objective: This research aimed to explore the long-term impact of COVID-19 pneumonia on the lung function after three months from recovery. Methods: Fifty subjects (age 18– 60 years) were recruited and classified into two groups: the control group (30 subjects) and the post-COVID-19 pneumonia group (20 patients). Pulmonary function tests, spirometry, body plethysmography [lung volumes and airway resistance (Raw)], diffusion capacity for carbon monoxide (DLCO), and fractional exhaled nitric oxide (FeNO), were measured after at least 3 months post-recovery. Results: Significant reduction in total lung capacity (TLC), forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1/FEV, and diffusing capacity for carbon monoxide (DLCO) was observed in post-COVID-19 subjects compared to controls. Restrictive lung impairment was observed in 50% of post-COVID-19 cases (n = 10) compared to 20% in the control group (n = 6, P = 0.026). In addition, mild diffusion defect was detected in 35% (n = 7) of the post-COVID-19 group compared to 23.3% (n = 7) in the controls (P = 0.012). Conclusion: COVID-19 pneumonia has an impact on the lung functions in terms of restrictive lung impairment and mild diffusion defect after three months from recovery. Therefore, a long-term follow-up of the lung function in post-COVID-19 survivors is recommended.

15 February 2018 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
AAAmani M. Al-Amodi
Amani M. Al-Amodi
NGNeda Z. Ghanem
Neda Z. Ghanem
SASumayh A. Aldakeel
Sumayh A. Aldakeel
LALubna Al-Asoom
Lubna Al-Asoom
NANazish Rafique Ahmed
Nazish Rafique Ahmed
J Francis BorgioJ Francis Borgio
J Francis Borgio
Introduction: Detection of β-thalassemia trait or carriers (β-TT) depends significantly on an increase in Hemoglobin A2 (HbA2) levels, which is found at low levels (<3%) in normal healthy individuals and elevated levels (≥3.5%) in β-TT individuals. The study was designed to evaluate the reliability of the diagnostic parameter HbA2 in the differentiation of β-TT and non-β-TT in Saudis. Methods: The widely used high performance liquid chromatography (Variant II Bio-Rad) was used to measure HbA2 levels in blood. Sanger sequencing was used to screen the variation in globin genes (HBB, HBD, HBA1, and HBA2). All the study subjects were divided into βTT and non-βTT (wild) categories based on the presence or absence of HBB variations and further sub-divided into false positive, true positive, false negative, and true negative, based on HbA2 values. Results: Out of 288 samples, 96 had HBB gene mutations. Of the 96 β-TT samples, sickle cell trait (SCT) samples (n = 58) were excluded, while the remaining (38 β-TT) were included in the detailed analysis: seven subjects with the HBB mutation had normal HbA2 (4%). Based on HbA2 analysis alone, both these groups would be incorrectly diagnosed as normal. Similarly, of the 189 non-β-TT samples, 179 had normal HbA2, eight had borderline HbA2, and two had a HbA2 level above 4%. Based on HbA2 analysis alone, borderline and >4% HbA2 individuals, negative for β-TT, can be incorrectly diagnosed as carriers. Conclusion: Given the percentage of samples falling in the HbA2 “borderline” and “normal” categories, it can be concluded that HbA2 has a measure of unreliability in the diagnosis of β-thalassemia carriers.

1 October 2020 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
NRNazish Rafique
Nazish Rafique
LALubna Al-Asoom
Lubna Al-Asoom
RLRabia Latif
Rabia Latif
AAAhmed Alsunni
Ahmed Alsunni
ASAyad Salem
Ayad Salem
LALaila Abbas Albaghli
Laila Abbas Albaghli
Purpose: This study aimed to determine the prevalence of migraine in young female adults and to identify if a relationship exists between psychological stress or poor sleep quality and migraine. Materials and Methods: This case control study was carried out at Imam Abdulrahman Bin Faisal University (IAU), Dammam, KSA from March 2019 to March 2020 on 1,990 female students (17- to 26-years-old). The study tools were Migraine Screening Questionnaire (MS-Q), International Headache Society (IHS) Criteria for Migraine, K10 Psychological Distress Instrument (K10) and Pittsburgh Sleep Quality Index (PSQI). Results: A total of 103 out of 1,990 (5.17%) participants were identified to have migraine. Migraineurs compared to controls had significantly higher average stress scores; felt more tired, nervous, restless, could not sit still, felt that everything was an effort, and nothing cheered them up (p values; 0.008, 0.001, 0.02, 0.01, 0.004, 0.009, 0.02 respectively). Moreover, presence of migraine was significantly correlated with various stress parameters including “High K10 scores,” “being tired,” “being nervous,” “restlessness,” “inability to sit still,” and “feeling that everything is an effort” (p values: 0.01, 0.002, 0.018, 0.01,0.005, 0.01,0.02). Regarding sleep quality and sleep parameters, no statistically significant difference was found between migraineurs and controls. No correlation was found between presence of migraine and poor sleep quality. Conclusions: The results of this study indicate that 5.17% of young females (17- to 26-years-old) suffer from migraine. It also concludes that poor sleep quality is not correlated with migraine, whereas high stress scores are significantly correlated with migraine in young female adults.

1 July 2022 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
LALubna Al-Asoom
Lubna Al-Asoom
Obesity is one of the major health-threatening conditions nowadays. Nigella sativa (NS) is a medicinal plant that demonstrates multiple therapeutic effects. In the current review, we aim to evaluate the weight lowering effect of NS in both clinical trials and experimental studies and to explore the possible reported mechanisms of this effect. We searched PubMed and Web of science and retrieved 14 clinical trials and 5 experimental studies that justify our inclusion criteria. After the analysis of these articles, we can conclude that long-term administration of NS for 6– 12 weeks can significantly lower bodyweight and other anthropometric indices. NS-oil is more potent than NS-powder in lowering bodyweight probably due to the higher concentration of fatty acids and thymoquinone. The weight lowering effect of NS is not a toxic effect, it conversely and preferably lowers the elevated liver enzymes in condition of fatty liver. It is also frequently accompanied by positive metabolic modifications, such as enhancement of lipid profile, lowering blood glucose and improving insulin resistance. Possible mechanisms for NS-bodyweight lowering effect might include an appetite-suppression effect, lowering caloric-intake and inhibition of intestinal glucose absorption. However, further experimental evidence is required to support these mechanisms or unveil new ones.